PMID- 35547749
OWN - NLM
STAT- MEDLINE
DCOM- 20220517
LR  - 20220716
IS  - 1838-7640 (Electronic)
IS  - 1838-7640 (Linking)
VI  - 12
IP  - 7
DP  - 2022
TI  - Optimized mobilization of MHC class I- and II- restricted immunity by dendritic 
      cell vaccine potentiates cancer therapy.
PG  - 3488-3502
LID - 10.7150/thno.71760 [doi]
AB  - Background: The participation of major histocompatibility complex (MHC) in 
      antigen presentation shapes both the breadth and magnitude of specific T cell 
      response. Dendritic cells (DCs) activated with nucleic acid or protein that 
      encodes/incorporates multiple antigenic epitopes elicit MHC class I- and II- 
      biased immunity, respectively. Studies demonstrate that an elevated MHC class 
      I-directed CD8(+) cytotoxicity T lymphocyte (CTL) response is able to provide 
      survival benefits to patient with malignant tumor. However, a fully effective 
      cancer therapy must elicit a diverse repertoire of both CD4(+) and CD8(+) T cell 
      responses, raising demands on a multifaceted activation of the MHC system. 
      Current therapeutic strategies usually lack an orchestrated mobilization of the 
      MHC class I and II responses. Vaccines with little synergistic effect or 
      unmanageable elicitation of the CD4(+) and CD8(+) T cell immunity usually fail to 
      induce a potent and durable anti-tumor protection. Methods: Here, cationic 
      nanoemulsions (CNEs) complexed with full-length tumor model antigen ovalbumin 
      (OVA) in the form of mRNA or protein were constructed and used as two antigenic 
      platforms to prepare DCs vaccines with tailored MHC participation (i.e., mRNA-DCs 
      and protein-DCs). In exploring a vaccine regimen with optimal tumor suppressing 
      effect, the mixing ratio of mRNA-DCs and protein-DCs was manipulated. Results: 
      Therapeutic DCs vaccines involving both antigenic platforms induced better 
      anti-tumor immunity in murine E.G7-OVA lymphoma model and B16-OVA melanoma model, 
      which can be further augmented upon a meticulous reallocation of the MHC class I 
      and II responses. Conclusion: This work indicated that a simultaneous and 
      coordinated mobilization of the MHC-restricted immunity might potentiate cancer 
      therapy.
CI  - (c) The author(s).
FAU - Shi, Yingying
AU  - Shi Y
AD  - College of Pharmaceutical Sciences, Zhejiang University, 866 Yuhangtang Road, 
      Hangzhou, Zhejiang 310058, P. R. China.
FAU - Liu, Yu
AU  - Liu Y
AD  - College of Pharmaceutical Sciences, Zhejiang University, 866 Yuhangtang Road, 
      Hangzhou, Zhejiang 310058, P. R. China.
FAU - Huang, Jiaxin
AU  - Huang J
AD  - College of Pharmaceutical Sciences, Zhejiang University, 866 Yuhangtang Road, 
      Hangzhou, Zhejiang 310058, P. R. China.
FAU - Luo, Zhenyu
AU  - Luo Z
AD  - College of Pharmaceutical Sciences, Zhejiang University, 866 Yuhangtang Road, 
      Hangzhou, Zhejiang 310058, P. R. China.
FAU - Guo, Xuemeng
AU  - Guo X
AD  - College of Pharmaceutical Sciences, Zhejiang University, 866 Yuhangtang Road, 
      Hangzhou, Zhejiang 310058, P. R. China.
FAU - Jiang, Mengshi
AU  - Jiang M
AD  - College of Pharmaceutical Sciences, Zhejiang University, 866 Yuhangtang Road, 
      Hangzhou, Zhejiang 310058, P. R. China.
FAU - Li, Xiang
AU  - Li X
AD  - College of Pharmaceutical Sciences, Zhejiang University, 866 Yuhangtang Road, 
      Hangzhou, Zhejiang 310058, P. R. China.
FAU - Lu, Yichao
AU  - Lu Y
AD  - College of Pharmaceutical Sciences, Zhejiang University, 866 Yuhangtang Road, 
      Hangzhou, Zhejiang 310058, P. R. China.
FAU - Liu, Xu
AU  - Liu X
AD  - College of Pharmaceutical Sciences, Zhejiang University, 866 Yuhangtang Road, 
      Hangzhou, Zhejiang 310058, P. R. China.
FAU - Shan, Xinyu
AU  - Shan X
AD  - College of Pharmaceutical Sciences, Zhejiang University, 866 Yuhangtang Road, 
      Hangzhou, Zhejiang 310058, P. R. China.
FAU - Luo, Lihua
AU  - Luo L
AD  - College of Pharmaceutical Sciences, Zhejiang University, 866 Yuhangtang Road, 
      Hangzhou, Zhejiang 310058, P. R. China.
FAU - You, Jian
AU  - You J
AD  - College of Pharmaceutical Sciences, Zhejiang University, 866 Yuhangtang Road, 
      Hangzhou, Zhejiang 310058, P. R. China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220424
PL  - Australia
TA  - Theranostics
JT  - Theranostics
JID - 101552395
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (RNA, Messenger)
RN  - 9006-59-1 (Ovalbumin)
SB  - IM
MH  - Animals
MH  - Antigens, Neoplasm
MH  - *CD4-Positive T-Lymphocytes
MH  - Dendritic Cells
MH  - Histocompatibility Antigens Class I
MH  - Humans
MH  - *Melanoma, Experimental
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Ovalbumin
MH  - RNA, Messenger/metabolism
PMC - PMC9065178
OTO - NOTNLM
OT  - MHC-restricted immunity
OT  - cancer therapy
OT  - cationic nanoemulsions
OT  - mRNA-DCs
OT  - protein-DCs
COIS- Competing Interests: The authors have declared that no competing interest exists.
EDAT- 2022/05/14 06:00
MHDA- 2022/05/18 06:00
PMCR- 2022/01/01
CRDT- 2022/05/13 11:17
PHST- 2022/02/06 00:00 [received]
PHST- 2022/03/12 00:00 [accepted]
PHST- 2022/05/13 11:17 [entrez]
PHST- 2022/05/14 06:00 [pubmed]
PHST- 2022/05/18 06:00 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - thnov12p3488 [pii]
AID - 10.7150/thno.71760 [doi]
PST - epublish
SO  - Theranostics. 2022 Apr 24;12(7):3488-3502. doi: 10.7150/thno.71760. eCollection 
      2022.